The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | The current and future management of myeloma in the second-line
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses updates presented at the IMS Annual Meeting 2024 that allow for refining the selection of second-line therapies in multiple myeloma (MM). Dr Fonseca mentions some of the key clinical trials influencing the choice of treatment strategy and comments on where the future of second-line therapy may go. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
